Dosis Sola Facit Venenum – The TAB08 (aka TGN1412) Relaunch

It is a while ago (2006) when TeGenero ran its ill-fated Phase 1 study of TGN1412, a CD28 superagonist slated for studies in diseases like rheumatoid arthritis and B-cell CLL. Unexpectedly, in this FIM study, TGN1412 generated a cytokine release syndrome (CRS), some called it “cytokine storm”, a massive T-cell Continue reading Dosis Sola Facit Venenum – The TAB08 (aka TGN1412) Relaunch

Treating GC in the Face of Dwindling Antibiotic Options – (1)

Looking across the Northern border it is clear that CDC Guidelines are not universally followed even in North America. Public Health Canada still recommends cefixime for uncomplicated gonorrhea (GC), albeit at the high single oral dose of 800 mg [1]. In the US, CDC has opted for combination treatment with ceftriaxone Continue reading Treating GC in the Face of Dwindling Antibiotic Options – (1)

Vaccine Mismatch – The Influenza Season 2014 / 2015

PLEASE SHARE YOUR OPINION AND VOTE BELOW   It has always been a bit of a gamble: Predicting the main circulating flu types and subtypes for the next season based on information from the previous season is an educated guess.  It works well most of the time but fails when there is Continue reading Vaccine Mismatch – The Influenza Season 2014 / 2015